Acute promyelocytic leukaemia is a rare but serious form of blood cancer that can develop suddenly, yet modern medicine has transformed it from one of the deadliest forms of leukaemia into a condition that can often be cured.

Understanding Acute Promyelocytic Leukaemia

Acute promyelocytic leukaemia, often called APL, is a rare type of blood cancer. It is actually a specific form of a broader disease known as acute myeloid leukaemia, which affects the blood-forming tissues in your body, particularly the bone marrow — the soft, spongy centre inside your bones where blood cells are made. Healthcare providers sometimes refer to this condition as APL leukaemia or M3-leukaemia.^[1]

In APL, something goes wrong at a very specific stage of white blood cell development. Normally, immature white blood cells called promyelocytes develop in the bone marrow and then mature into fully functioning white blood cells that help fight infections. However, in APL, these promyelocytes never fully mature. Instead, they multiply uncontrollably and build up in the bone marrow, crowding out the healthy blood cells your body needs.^[7]

What makes APL particularly concerning is how quickly symptoms can appear and worsen. The condition can become life-threatening within days if not treated promptly, especially because it often causes serious bleeding problems. However, there is encouraging news: thanks to significant advances in treatment over the past few decades, APL has been transformed from a rapidly fatal disease into one that can be cured in most cases.^[2]

Epidemiology: Who Gets APL?

Acute promyelocytic leukaemia is considered a rare disease. In the United States, approximately 600 to 800 people are diagnosed with APL each year, which means roughly one person in every 250,000 develops this condition.^[4][7] While these numbers may seem small, the impact on those affected and their families is profound.

APL accounts for about 10 to 15 percent of all newly diagnosed cases of acute myeloid leukaemia. This means that out of every 100 people diagnosed with AML, approximately 10 to 15 will have the specific APL subtype.^[11][5]

The disease typically affects adults in their middle years. Most people are diagnosed when they are around 40 years old, though some sources indicate that many receive their diagnosis in their 30s.^[1][4] However, APL does not discriminate by age entirely — it can also affect children, particularly those between eight and ten years old. In childhood cases of acute myeloid leukaemia, APL represents about 4 to 10 percent of all diagnoses.^[7]

Certain populations appear to have higher rates of APL. People of Hispanic ethnicity have been found to have an increased risk of developing this disease compared to other ethnic groups.^[7] Understanding these patterns helps doctors stay alert to the possibility of APL in patients who present with concerning symptoms.

What Causes Acute Promyelocytic Leukaemia?

Acute promyelocytic leukaemia is caused by a specific genetic change, or mutation, that occurs in the cells of your bone marrow. This is not a change you inherit from your parents or pass on to your children. Instead, it happens randomly during your lifetime, after you were conceived. Scientists still do not know what triggers this change to occur.^[1]

The genetic problem that causes APL involves two specific genes. One is called PML, which is located on chromosome 15. The other is called RARA (which stands for retinoic acid receptor alpha), located on chromosome 17. In more than 95 percent of APL cases, pieces of these two chromosomes break off and swap places in a process called a chromosomal translocation. This particular swap is written in medical notation as t(15;17).^[4][5]

When these two gene fragments join together, they create an abnormal hybrid gene called PML-RARα. This fusion gene produces a protein that works very differently from the normal proteins that PML and RARA would produce separately. The PML-RARα protein interferes with the normal development of white blood cells. It essentially blocks promyelocytes from maturing into healthy, functioning white blood cells. As a result, these immature cells get stuck at the promyelocyte stage and begin multiplying uncontrollably, crowding out the healthy blood cells and platelets your body needs.^[5]

In a small percentage of cases — about 2 to 5 percent — APL can be caused by translocations involving the RARA gene and other partner genes besides PML. These are much rarer and include genes such as PLZF, NPM, and others. Some of these rare variations respond differently to treatment, which is why identifying the exact genetic change is important.^[4]

Risk Factors for Developing APL

While the exact trigger for the genetic change that causes APL remains unknown, researchers have identified several factors that may increase a person’s risk of developing this disease. Understanding these risk factors can help both patients and doctors be more vigilant about symptoms.

Age is one factor to consider. Although APL can occur at any age, the risk increases as people get older, with most cases occurring in adults around age 40. However, there is also a smaller peak in childhood cases, particularly between ages eight and ten.^[7]

Ethnicity appears to play a role, with people of Hispanic origin showing higher rates of APL compared to other ethnic groups. The reasons for this increased risk are not fully understood and may involve a combination of genetic and environmental factors.^[7]

Obesity has been identified as a potential risk factor for developing acute promyelocytic leukaemia. Excess body weight may create an environment in the body that increases the likelihood of genetic mutations, though the exact mechanisms are still being studied.^[7]

Certain occupational exposures may also increase risk. People who work with toxic chemical agents, particularly benzene, which is found in some industrial settings and petroleum products, have a higher chance of developing APL. Additionally, exposure to electromagnetic fields in certain work environments has been suggested as a possible risk factor.^[7]

Previous cancer treatment is another important risk factor. Individuals who have been treated with chemotherapy or radiation therapy for another cancer may be at increased risk of developing APL later. This is sometimes called treatment-related or secondary leukaemia, and it can occur months or years after the initial cancer treatment.^[7]

It is important to remember that having one or more of these risk factors does not mean a person will definitely develop APL. Many people with these risk factors never develop the disease, while others with no known risk factors do. The disease remains largely unpredictable in terms of who it will affect.

Recognizing the Symptoms of APL

The symptoms of acute promyelocytic leukaemia develop because the bone marrow becomes filled with abnormal promyelocytes and can no longer produce adequate numbers of normal blood cells. This shortage affects all three main types of blood cells: red blood cells, white blood cells, and platelets. When blood cell levels drop dangerously low — a condition called pancytopenia — people experience a range of symptoms that can develop suddenly and worsen rapidly.^[1]

One of the most common symptoms is extreme tiredness or fatigue. This happens because of anaemia, which means you do not have enough red blood cells to carry oxygen throughout your body. People with anaemia often feel exhausted even after resting, and they may appear unusually pale.^[1][8]

Frequent infections are another warning sign. Because APL crowds out the healthy white blood cells that fight off bacteria and viruses, people with this condition are more vulnerable to infections. They may develop fevers repeatedly or find that minor infections become more serious than expected.^[1]

Unintentional weight loss can occur in people with APL. This happens because the cancer speeds up the body’s metabolism, causing it to burn through energy from food more quickly than normal. People may lose weight without trying or notice a significant loss of appetite.^[1]

Joint and bone pain are also possible symptoms. The abnormal cells can spread to the bones and joints, causing discomfort or pain in those areas.^[7]

Bleeding Symptoms: The Most Dangerous Sign

The most distinctive and dangerous symptoms of APL involve bleeding problems. This happens for two reasons: first, people with APL have very low levels of platelets, which are the tiny cell fragments that help blood clot and stop bleeding. Second, the leukaemia cells release substances that interfere with the body’s normal clotting system, sometimes causing a serious condition called disseminated intravascular coagulation.^[2]

Bleeding symptoms can take many forms. People may notice easy bruising, where even minor bumps cause large bruises to appear. They might see small red or purple dots under their skin, called petechiae, which are caused by tiny bleeding spots. Nosebleeds that happen frequently or are difficult to stop are common. Gums may bleed easily, especially when brushing teeth. Women may experience unusually heavy menstrual bleeding. Blood may appear in the urine, a condition called haematuria.^[5][8]

More serious bleeding can occur in the digestive system, causing stools to appear black and tarry or to have visible streaks of red blood. The most dangerous complication is bleeding inside the brain, called intracranial haemorrhage, which can cause severe headaches, vision problems, weakness in the arms or legs, or difficulty with coordination and movement.^[1]

Prevention: Can APL Be Prevented?

Unfortunately, there is currently no known way to prevent acute promyelocytic leukaemia. Because the genetic change that causes APL occurs randomly during a person’s lifetime and scientists do not yet understand what triggers this change, there are no specific lifestyle changes, vaccinations, or screening tests that can prevent the disease from developing.^[5]

However, being aware of the risk factors may help some people reduce their overall risk of developing leukaemia. For instance, avoiding occupational exposure to benzene and other toxic chemicals, when possible, may lower the risk. Maintaining a healthy weight through balanced diet and regular physical activity might also be beneficial, given that obesity has been identified as a risk factor.^[7]

For people who have previously been treated for cancer with chemotherapy or radiation, there is no way to prevent the small risk of developing treatment-related leukaemia. However, being aware of this possibility and monitoring for symptoms can help ensure early detection if APL does develop.

The most important aspect of “prevention” in APL is really early detection and rapid treatment. Because APL progresses so quickly and can be fatal within days if untreated, recognizing symptoms early and seeking immediate medical care is crucial. People who are aware of the warning signs — especially unexplained bleeding and bruising — are more likely to get diagnosed and treated quickly, which dramatically improves their chances of survival and cure.

How the Disease Affects the Body: Pathophysiology

To understand how acute promyelocytic leukaemia affects the body, it helps to know what normally happens in healthy bone marrow. The bone marrow contains special cells called haematopoietic stem cells, which are like master cells that can develop into any type of blood cell. These stem cells gradually mature through several stages, eventually becoming red blood cells that carry oxygen, white blood cells that fight infection, or platelets that help blood clot.^[5]

In APL, the normal development process is disrupted at a very specific point. When the abnormal PML-RARα fusion protein is produced, it interferes with the genes that control white blood cell maturation. Specifically, this protein blocks the signals that would normally tell promyelocytes to mature into fully developed white blood cells called granulocytes.

The PML-RARα protein works by binding very tightly to specific sites on the cell’s DNA. Once attached, it recruits other molecules that suppress the genes responsible for cell maturation. It is like putting a lock on the cellular machinery that would normally allow the cells to grow up. The protein also interferes with the normal function of the wild-type PML protein, which normally acts as a tumour suppressor — meaning it helps prevent cells from multiplying uncontrollably.^[4]

As a result of this blockage, the promyelocytes become stuck in their immature state. Not only do they fail to mature, but they also begin to multiply rapidly and without control. These abnormal promyelocytes accumulate in the bone marrow, taking up space that should be occupied by healthy blood cell precursors. Eventually, the bone marrow becomes so crowded with these dysfunctional cells that it cannot produce adequate numbers of normal red blood cells, healthy white blood cells, or platelets.^[7]

The shortage of red blood cells leads to anaemia, causing fatigue, pale skin, and shortness of breath. The lack of normal, functioning white blood cells leaves the body vulnerable to infections. The deficit of platelets, combined with the release of clot-promoting substances from the abnormal promyelocytes, creates severe bleeding problems and the risk of disseminated intravascular coagulation.

In disseminated intravascular coagulation, the blood’s clotting system becomes overactive throughout the body, forming tiny clots in small blood vessels. This uses up the body’s supply of clotting factors and platelets, which paradoxically leads to severe bleeding because there are no longer enough clotting resources left to stop bleeding when it occurs. This is one of the most dangerous complications of APL and can happen very early in the disease, even before diagnosis.^[2]

Once the abnormal promyelocytes fill up the bone marrow, they can spill over into the bloodstream and spread to other parts of the body. They may infiltrate the bones themselves, causing pain, or accumulate in other organs, though this is less common than in some other types of leukaemia.^[7]

What makes APL unique among leukaemias, and what offers hope for patients, is that the PML-RARα fusion protein can be targeted by specific treatments. When patients are given a medication called all-trans retinoic acid, or ATRA, it binds to the abnormal fusion protein and forces the blocked promyelocytes to resume their maturation process. This allows them to differentiate into more mature cells that can no longer multiply uncontrollably. This mechanism, called differentiation therapy, is quite different from traditional chemotherapy that simply kills cancer cells, and it is one of the major reasons why APL has become so treatable.^[2]